Bio Pharma Dive

APRIL 25, 2025

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as critical to Biohaven’s future.

Genetics 267

Genetics Marketing Development Drugs 267

Pharmaceutical Technology

JULY 1, 2024

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

Marketing 299

Marketing 299

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing 344

Marketing 344

Drug Patent Watch

JANUARY 13, 2025

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

Marketing 73

Marketing Insulin Generic Drugs Medicine 73

Pharma Marketing Network

MARCH 26, 2025

Artificial intelligence (AI) is no longer a futuristic concept in healthcareits here, embedded in nearly every touchpoint of modern pharma marketing. But as pharma marketers race to adopt these tools, a central question looms: Is AI fueling smarter engagement, or setting the stage for a compliance disaster? Key pillars include: 1.

Compliance 64

Compliance Marketing Regulation Pharma Companies 64

Bio Pharma Dive

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 315

Marketing 315

XTalks

FEBRUARY 5, 2025

The approval marks Celltrions seventh biosimilar to be granted marketing authorization in the US and its fifth immunology biologic approval. The approval encompasses both intravenous (IV) and subcutaneous (SC) formulations, offering flexibility in administration.

FDA Approval 102

FDA Approval Marketing Antibody Immune Response 102

Pharmaceutical Technology

JUNE 28, 2024

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.

Marketing 264

Marketing 264

Pharmaceutical Technology

MARCH 3, 2025

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years old.

Vaccine 162

Vaccine Vaccination Marketing 162

Pharmaceutical Technology

APRIL 23, 2025

The lawsuit filings are the latest turn in a long-running legal saga between GLP-1RAs makers and compounders.

Marketing 240

Marketing 240

Bio Pharma Dive

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 280

Trials Drugs Marketing 280

Bio Pharma Dive

JANUARY 19, 2023

“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

Marketing 336

Marketing Drugs 336

Bio Pharma Dive

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 255

Marketing Drugs 255

Pharma Marketing Network

APRIL 10, 2025

In today’s competitive healthcare landscape, PPC campaigns (Pay-Per-Click advertising) have emerged as a critical lever for pharma marketers aiming to deliver timely, targeted, and measurable impact. Strategic Audience Targeting and Keyword Planning One of the key advantages of PPC campaigns in pharma marketing is their precision.

Marketing 52

Marketing Branding Compliance Pharma Companies 52

Pharmaceutical Technology

OCTOBER 18, 2024

Late-stage pipeline products could drive combined sales of approximately $171.4 million by 2033 in the 8MM.

Sales 269

Sales Marketing Production 269

Pharmaceutical Technology

APRIL 28, 2025

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC).

Marketing 130

Marketing 130

Pharmaceutical Technology

APRIL 9, 2025

The EC has granted marketing authorisation for AbbVie's once-a-day treatment Rinvoq (upadacitinib) 15mg for adults with GCA.

Marketing 130

Marketing 130

Pharmaceutical Technology

NOVEMBER 8, 2024

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Marketing 240

Marketing 240

Pharma Marketing Network

APRIL 11, 2025

This is where SEO marketing strategies become essentialallowing brands to boost visibility, earn trust, and support both HCP and patient journeys without violating regulatory guidelines. SEO marketing strategies** enable brands to reach audiences actively searching for information about diseases, treatments, side effects, and support.

Marketing 52

Marketing Branding Regulation Production 52

Pharmaceutical Technology

AUGUST 12, 2024

As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.

Pharma Companies 264

Pharma Companies Antibody Marketing Drugs 264

Pharmaceutical Technology

JUNE 27, 2024

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

Marketing 244

Marketing 244

Pharmaceutical Technology

APRIL 4, 2025

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms of action.

Marketing 130

Marketing Production 130

Pharmaceutical Technology

APRIL 14, 2025

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is forecast to grow from $11.6bn in 2023 to $30.2bn by 2033, representing a compound annual growth rate of 10%, according to leading data and analytics company GlobalData.

Marketing 130

Marketing 130

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 15, 2024

(Abdullah Durmaz/Getty Images) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease. But the price of these injections is steep: They cost about […]

Marketing 246

Marketing Branding Drugs Clinical Trials 246

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing 245

Marketing 245

Bio Pharma Dive

MARCH 24, 2025

Understanding private sector breakthroughs, acquisitions and funding is critical in a volatile market.

Marketing 157

Marketing 157

Pharmaceutical Technology

APRIL 16, 2025

AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Marketing 130

Marketing Production 130

Pharmaceutical Technology

NOVEMBER 6, 2024

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.

Marketing 263

Marketing Drugs 263

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs 278

Drugs Marketing 278

Pharmaceutical Technology

FEBRUARY 14, 2025

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the UK, and Japan - is projected to experience significant growth, with sales increasing from $2.3bn in 2023 to $5.2bn by 2033, according to leading data and analytics company GlobalData.

Marketing 147

Marketing Sales 147

Pharmaceutical Technology

JANUARY 21, 2024

CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.

Manufacturing 246

Manufacturing Marketing Development 246

Bio Pharma Dive

MARCH 26, 2025

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

Drugs 326

Drugs Marketing 326

Bio Pharma Dive

FEBRUARY 2, 2023

The company’s lead drug could be an oral alternative to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly.

Marketing 360

Marketing Drugs 360

Bio Pharma Dive

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 325

Drugs Marketing 325

Bio Pharma Dive

SEPTEMBER 12, 2024

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

Marketing 330

Marketing 330

Bio Pharma Dive

FEBRUARY 6, 2022

For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.

Drugs 364

Drugs Marketing 364

Bio Pharma Dive

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Drugs 329

Drugs Marketing 329